Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769129 | PMC |
| http://dx.doi.org/10.1097/CM9.0000000000001538 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessment of clinical characteristics and mortality in patients hospitalized with SARS-CoV-2 from January 2022 to November 2022, when Omicron variants were predominant in the United States.
Curr Med Res Opin
January 2025
Pfizer Inc., US Medical Affairs, New York, NY, USA.
Objective: To describe the demographic/clinical characteristics, treatment patterns, and mortality among patients hospitalized with COVID-19 during Omicron predominance by immunocompromised and high-risk status.
Methods: Retrospective observational study of patients hospitalized with COVID-19 between January 1, 2022 and November 30, 2022, using data from the Optum de-identified Clinformatics® Data Mart Database. Patient demographic/clinical characteristics, treatments, mortality and costs, were assessed, during the emergence of BA.
Complex management of GS (Good's syndrome) with persistent COVID-19 infection and polymicrobial infections: A case report.
Heliyon
January 2025
Zhongshan Hospital (Xiamen), Fudan University, Xiamen City, 361015, China.
This case report highlights the diagnostic and therapeutic complexities faced by a 56-year-old female with Good's syndrome (GS), who presented with persistent Coronavirus Disease 2019 (COVID-19) infection alongside spp, , and co-infection, which collectively contributed to severe pulmonary involvement. The report further emphasizes a multifaceted treatment approach, incorporating antivirals, antifungals, antimicrobials, immunoglobulins, and antifibrotic therapy, which ultimately led to an improvement in the patient's condition. It underscored the intricate challenges of managing immunocompromised patients with multiple concurrent infections.
View Article and Find Full Text PDFStudy of Outcomes of Mucormycosis in COVID-19 Patients at a Tertiary Care Hospital in Central India: A Retrospective Study.
Cureus
December 2024
Department of Medicine, Government Medical College and Hospital, Nagpur, IND.
Background The COVID-19 pandemic has posed unprecedented challenges to the global healthcare system. Among the various complications, mucormycosis, a fungal infection caused by the Mucorales order, has emerged as a significant threat, particularly in immunocompromised individuals. This study aims to evaluate the outcomes of mucormycosis in COVID-19 patients treated at a tertiary care hospital in Central India.
View Article and Find Full Text PDFEfficacy and safety of antiviral therapies for the treatment of persistent COVID-19 in immunocompromised patients since the Omicron surge: a systematic review.
J Antimicrob Chemother
January 2025
Division of Infectious Diseases, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, University of Cologne, Kerpener Str. 62, 50939 Cologne, Germany.
Background: Persistent COVID-19 (pCOVID-19) in immunocompromised patients is characterized by unspecific symptoms and pulmonary infiltrates due to ongoing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) replication. Treatment options remain unclear, leading to different approaches, including combination therapy and extended durations. The purpose of this study was to assess the efficacy and safety of antiviral therapies for pCOVID-19 in immunocompromised patients since the Omicron surge.
View Article and Find Full Text PDFSafety of Nirmatrelvir-Ritonavir Administration in Children With Immunodeficiency and/or Comorbidities With SARS-CoV-2 Infection: A Retrospective Clinical Report.
Pediatr Infect Dis J
December 2024
Medical Directorate, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Introduction: Despite the generally mild course of COVID-19 in children, immunocompromised patients may experience complications or severe infection. This study reports the clinical outcomes of pediatric patients treated with nirmatrelvir and ritonavir (N/R) for SARS-CoV-2 infection.
Methods: We retrospectively reported the data of children with any immunodeficiency with COVID-19 who received N/R treatment between March 2022 and June 2023 at the Bambino Gesù Children's Hospital.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!